increased numbers of Treg [9] [10] [11] [12] [13] [14] 22, 23] . Vaccination with recombinant vaccinia virus, encoding haemaglutinin from influenza virus, expanded the number of Treg in spleen as much as 30-fold [14] . To overcome this phenomenon and to enhance immune responses, the effect of temporal depletion or inactivation of Treg in combination with immunotherapeutic strategies is currently being evaluated in mice and humans [1] [2] [3] [4] [5] [6] [7] [8] .
We have developed a viral vector-based therapeutic vaccine against malignancies induced by human papillomavirus (HPV). The recombinant viral vector, which is based on an alphavirus, Semliki Forest virus (SFV), encodes a fusion protein of E6 and E7 from HPV type 16 (SFVeE6,7) [24, 25] . We demonstrated that immunization with SFVeE6,7 replicon particles results in strong HPV-specific cellular responses and eradication of established HPV-transformed tumours. Moreover,
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tolerance can be broken in transgenic mice immune tolerant for HPV [26] [27] [28] [29] . The present study was set out to explore whether SFV-based immunization strategies can be further optimized by regimes to suppress Treg.
One of the strategies to suppress Treg is to use depleting antibodies specific for Treg. Treg are a phenotypically heterogeneous population coexpressing markers such as CD4, CD25, CTLA4, GITR and Foxp3 [30, 31] . The transcription factor Foxp3 is one of the key controllers of Treg development and its expression is essential to establish a functional Treg lineage [32] [33] [34] [35] [36] .
Although CD25 is also expressed on activated T-cells, anti-CD25 antibodies are often used to deplete Treg in animal model studies and recently also in clinical studies [2, 4, [37] [38] [39] . However, depletion of Foxp3 + Treg using anti-CD25 is partial and short-lived [40, 41] . Furthermore, recently Curtin et al. [42] showed that Treg depletion in mice using PC61 (one of the anti-CD25 clones) also inhibits clonal expansion of tumour antigen-specific T-cells.
A very promising novel antibody to study the role of Treg depletion on immune responses is an antibody recognizing folate receptor 4 (FR4). Treg constitutively express high amounts of FR4, distinguishing them from other T-cells. Administration of anti-FR4 antibody as such, that is, without concomitant immunization, already induces anti-tumour immunity in tumour-bearing mice [43] .
In this study we first determined if SFVeE6,7 immunization, as described for other cancer immunization strategies, results in an enhanced number or activity of Treg. Next we evaluated if combining SFVeE6,7 primeboost immunization with Treg depletion through coadministration of anti-FR4 antibody further improves the immune effectiveness of the SFVeE6,7 immunization strategy.
Methods
Cell lines
Baby hamster kidney cells (BHK-21) were obtained from the American Type Culture Collection (number CCL-10; Manassas, VA, USA). C3 cells, 13-2 cells and TC-1 cells were a kind gift from C Melief and R Offringa (Leiden University Medical Center, Leiden, the Netherlands). All cells were cultured as described previously [27] .
Mice
Specified pathogen-free female C57BL/6 mice were used at 6-10 weeks of age. They were purchased from Harlan CPB (Zeist, the Netherlands) and kept according to institute guidelines. All animal experiments were approved by the local Animal Experimentation Ethical Committee (the Institutional Animal Care and Use Committee of the University of Groningen, Groningen, the Netherlands).
Production, purification and titre determination of SFVeE6,7 particles
The production, purification and titre determination of recombinant SFVeE6,7 was performed as described previously [24] . In brief, pSFV3-eE6,7 was produced using pSFV-helper 2 and purified on a discontinuous sucrose density gradient. Before use, SFV particles were activated with 1/20 volume of α-chymotrypsin (10 mg/ml; Sigma Chemical Co., St Louis, MO, USA). SFV particles were titrated using BHK-21 cells. pSFV3-eE6,7 encodes an enhanced expression of a fusion product of E6 and E7 of HPV type 16.
SFVeE6,7 immunizations and anti-FR4 treatment
Mice were immunized intramuscularly with different amounts of SFVeE6,7 (10 5 -10 7 particles), followed by one booster immunization with a 2-week interval. 1 day before each immunization, in some experiments, mice were injected intraperitoneally with 25 µg anti-FR4 (TH6 clone) antibody. Anti-FR4 antibody was a kind gift from S Sakaguchi (Kyoto University, Kyoto, Japan). Mice injected intramuscularly and/or intraperitoneally with phosphate-buffered saline were negative controls.
Treg, major histocompatibility complex class I tetramer staining and FACS analysis Spleen cells and peripheral blood mononuclear cells (PBMCs) obtained from immunized and control mice at the indicated time points were stained with fluorescein isothiocyanate (FITC)-conjugated anti-CD8 (ProImmune, Oxford, UK) and phycoerythrin (PE)-conjugated major histocompatibility complex (MHC) class I tetramers loaded with RAHYNIVTF (HPV16 E7 epitope; Sanquin, Amsterdam, the Netherlands). It allowed us to determine the frequency of HPV-specific cytotoxic T-lymphocytes (CTLs). To analyse Treg numbers, cells were stained with PE-conjugated anti-CD4 (SouthernBiotech, Birmingham, AL, USA), allophycocyanin (APC)-conjugated anti-CD25 (eBioscience, San Diego, CA, USA) and FITC-conjugated anti-CD127 (eBioscience). After washing, cells were permeabilized with Foxp3 staining buffer, set according to the manufacturer's instructions (eBioscience) and additionally stained with Alexa Fluor ® 700-conjugated antiFoxp3 (eBioscience). Cells were washed and measured by flow cytometry (LSR-II; BD Biosciences, Erembodegem, Belgium). Collected data was analysed with the Win-List software package (Verity Software House, Inc., Topsham, ME, USA).
Cell sorting
Freshly isolated splenocytes from SFVeE6,7-or PBSimmunized mice were stained with PE-conjugated anti- 
Regular CTL and micro-CTL assay
In a regular CTL assay, 10 days after the last immunization, spleen cells were isolated and cocultured with irradiated (100 grays) TC-1 cells in a ratio of 25 (maximal release − spontaneous release)] counts per min ×100. The spontaneous 51 Cr-release was always <15%. The standard errors of the means of the triplicate determinations were <10% of the mean. USA) was added. Cells were then harvested onto 96-well filters using a Mach III M Harvester (Tomtec, Inc., Hamden, CT, USA) and sealed in plastic bags containing 6 ml Betaplate Scint cocktail (Wallac, Inc., Turku, Finland). 
Proliferation assay
Tumour treatment experiments
Mice were inoculated subcutaneously in the neck with 2×10
4 TC-1 cells suspended in 0.2 ml Hank's Balanced Salt Solution (Invitrogen, Paisley, UK). After 10 days, the mice were immunized intramuscularly with 10 6 (low-dose) or 5×10 6 (high-dose) SFVeE6,7 particles and boosted twice with a 1-week interval. For Treg depletion, the mice were injected intraperitoneally with 25 µg anti-FR4 1 day before each SFVeE6,7 immunization. Control mice were injected intramuscularly and/or intraperitoneally with PBS. The same skilled technician performed the tumour measurements. When the tumour grew through the skin or if the tumour volume exceeded 1,000 mm 3 , the mice were killed.
Statistical analysis
Data are presented as the mean ±sd. Data were analysed using Student's t-test. The Cox proportional hazards test was used for statistical analysis of tumour treatment responses. Statistical significance was defined as P<0.05 (or as indicated).
Results
Induction of suppressor and effector T-cells by SFVeE6,7 immunization
Intravenous or intramuscular immunization with SFVeE6,7 induces strong cellular and anti-tumour responses in mice [24, [26] [27] [28] [29] . We reasoned that this strong immune activation might also induce a suppressive immune response, as described for other immunization strategies [9] [10] [11] [12] [13] [14] 22, 23, 44] . To investigate the influence of SFVeE6,7 immunization on induction of Treg, we analysed the frequencies of Treg and HPV-specific CTL in blood and spleen of mice immunized with SFVeE6,7. Treg were analysed by flow cytometry based on the expression of CD4 in blood. In spleen, no significant changes of these populations were observed 10 days after the booster immunization (MW et al., data not shown). The frequency of HPV-specific T-cells within the CD8 + T-cell population, with all dosages of SFVeE6,7 tested, increased to approximately 1% after the prime immunization. This frequency decreased on day 14 and significantly increased again after the booster immunization (Figure 1C; P<0.05) . These results suggest that SFVeE6,7 immunization does not augment the number of Treg in mice, but boosted HPV-specific CTL.
Influence of Treg addition on proliferation and lytic activity of HPV-specific CTL in vitro
Despite the fact that no Treg were induced by SFVeE6,7, existing Treg may affect the proliferation and/or lytic activity of antigen-specific T-cells induced by SFVeE6,7 immunization. We therefore investigated the effect of Treg on in vitro specific-CTL responses induced by SFVeE6,7. Treg were isolated from mice treated with SFVeE6,7 and from control mice by positive sorting for CD4 and CD25 cell surface expression. Purity of samples after sorting was >85% (Figure 2A ). Approximately 90% of the sorted CD4 + CD25
med/hi cells expressed Foxp3 (MW et al., data not shown). The isolated Treg suppressed proliferation of anti-CD3 and anti-CD28 stimulated spleen cells ( Figure 2B ). In the spleens of control mice, 1 in 50 spleen cells is a Treg.
The sorted CD4 + CD25 med/hi Treg were added to in vitro restimulation cultures of spleen cells isolated from SFVeE6,7-immunized mice. As the number of Treg that can be isolated from a mouse spleen is low, we set up a micro CTL assay. In this assay the spleen cells were cultured in 96-well plates and, after the 7-day restimulation with irradiated HPV-specific tumour cells, 51 Cr-labelled target cells were added to the restimulation cultures.
The cytolytic activity of the CTL was not influenced by the addition of Treg ( Figure 2C ). SFV immunization did not result in increased numbers of Treg in the spleen of immunized mice, as there was 1 Treg per 50 splenocytes. As 10% of the spleen cells is CD8 + and 1% of the CD8 + T-cells is E7-specific, this implies that in these mice there is 100 Treg per 5 E7-specific T-cells. Only the addition of 25-fold more Treg (that is, 1,000 Treg per 2 E7-specific CD8 + T-cells; in Figure 2C represented by the ratio 1 Treg: 2 spleen cells) resulted in a decrease in CTL activity. This decrease is due to suppression of proliferation of HPV-specific CD8 + T-cells during the restimulation protocol, as in a separate experiment wherein we demonstrated that the addition of Treg in the 4-h 51 Cr-release assay did not influence cytolysis (MW et al., data not shown). It should be noted that no differences were observed between the activity of Treg isolated from naive or SFVeE6,7-immunized mice ( Figure 2C ). Thus, Treg isolated from control or SFVeE6,7-immunized mice, up to a ratio of 1 Treg to 6 spleen cells, do not change the in vitro proliferation and lytic activity of HPV-specific CTL elicited by SFVeE6,7 immunization.
Changes in HPV-specific CTL responses after in vitro depletion of Treg
We next examined if depletion of CD4 + CD25
med/hi T-cells, of which >90% were Foxp3 + , enhances the in vitro proliferation and/or activity of HPV-specific T-cells. Spleen cells isolated from SFVeE6,7-immunized mice were depleted from CD4 + CD25 med/hi cells by cell sorting and subsequently restimulated in vitro before being tested in a 51 Cr-release assay. As a control, CD4
+ CD25 med/hi -depleted spleen cells were also reconstituted with CD4 + CD25 med/hi T-cells to the original ratio found in the spleen. In addition, in vitro restimulated cultures of unsorted spleen cells from SFVeE6,7-immunized mice and spleen cells from nonimmunized control mice were analysed. In Figure 3A , a typical flow cytometry analysis of one of the spleen populations before and after sorting is depicted. The sorted population contained <0.2% CD4 + CD25
med/hi T-cells as opposed to 2% in the unsorted population. Depletion of CD4 + CD25 med/hi T-cells before in vitro restimulation did not influence the cytolytic activity of HPV-specific CTL compared to the activity measured in reconstituted and unsorted spleen cells ( Figure 3B ). Thus, depletion of Treg does not enhance SFVeE6,7-specific CTL response.
Influence of in vivo Treg depletion on the immune response induced by SFVeE6,7 immunization
Growing evidence in the literature indicates that immune responses induced by immunization are enhanced after in vivo Treg elimination [1] [2] [3] [4] [5] [6] [7] [8] . We therefore set out to investigate if in vivo depletion of Treg can also enhance the in vivo induction of HPV-specific CTL by SFVeE6,7 immunization.
As still relatively few studies have been performed with anti-FR4, the efficacy of this antibody to deplete Treg in vivo was investigated. Mice were injected with a single dose of anti-FR4. At the indicated time points, PBMCs were analysed by flow cytometry. As presented in Figure 4A T-cells was depleted at the time of SFVeE6,7 immunization ( Figure 4B ). However, despite this strong Treg depletion, the frequency of SFVeE6,7-induced HPVspecific CD8 + T-cells in spleen, as determined 10 days after the booster immunization, was not higher than the frequency reached after SFVeE6,7 immunization alone ( Figure 5A ). This result suggests that the in vivo priming (that is, the interaction and activation + T-cells ( Figure 5B  and 5C ). These results suggest that in vitro proliferation of SFVeE6,7-induced T-cells is presumably at an optimal level, not being further enhanced by decreased numbers of suppressor cells. However, more importantly, these S F V e E 6 , 7 S F V e E 6 , 7 + a n t i -F R 4 A n t i -F R 4 P B S A B Mice were immunized (day 0) and boosted (day 14) intramuscularly with 10 6 Semliki Forest virus expressing a fusion protein of E6 and E7 of human papillomavirus type 16 (SFVeE6,7; n=6) or phosphate-buffered saline (PBS; n=6). In each immunization group three mice also received an intraperitoneal injection with 25 µg anti-folate receptor 4 (FR4; day -1 and day 13). At 10 days after the final injection, the mice were killed and spleen cells were isolated. (A) Freshly isolated splenocytes, as well as 5 and 7 days in vitro restimulated cells, were analysed by flow cytometry after staining with RAHYNIVTF-carrying major histocompatibility complex class I tetramers and anti-CD8. The dashed line represents background level. After (B) 5 and (C) 7 days of in vitro restimulation, cytolytic activity against C3 target cells was determined by triplicate assay using 96-well plates. The levels of specific cytolysis against the target cells at different effector:target ratios are shown. Error bars represent standard deviation. data demonstrate that in vivo depletion of Treg does not affect the priming phase of immune responses elicited by SFVeE6,7 immunization.
Therapeutic efficacy of immunization with SFVeE6,7 in combination with Treg depletion
We analysed if depletion of Treg would stimulate the therapeutic efficacy of SFVeE6,7 in vivo. To allow detection of an effect of the elimination of Treg, the immunization protocol was chosen such that a suboptimal therapeutic effect was attained. We previously have shown that immunization with 5×10 6 infectious units of SFVeE6,7 at days 7-14 and 21 after tumour inoculation results in the elimination of tumours in 100% of mice [29] . We therefore primed immunized mice 10 days after tumour inoculation with 10 6 or 5×10 6 infectious units of SFVeE6,7. The mice were boosted twice, with a 1-week interval (days 17 and 24). Some of the mice were also injected with anti-FR4, to deplete Treg, 1 day before each immunization. It was found that 2 days after anti-FR4 injection the Treg level within the TC-1 tumour was decreased by 55% compared to control values (MW et al., data not shown). Starting from day 10, tumour size was measured twice weekly by palpation. All control mice, injected intramuscularly with PBS, developed tumours and had to be killed within 32 days after tumour inoculation ( Figure 6 ). The group of mice treated with anti-FR4 alone did not show a delay in tumour growth compared to the buffer control mice. All other immunization protocols resulted in delayed tumour growth when compared with the PBS-treated group (P<0.05). No substantial difference in outcome was observed between the groups immunized with SFVeE6,7 alone and groups immunized with SFVeE6,7 combined with Treg depletion. At 50 days after tumour inoculation, one and two out of seven mice were tumour-free in groups treated with 10 6 infectious units SFVeE6,7 alone or 10 6 infectious units SFVeE6,7 combined with anti-FR4, respectively. In the groups immunized with 5×10 6 of SFVeE6,7 with or without anti-FR4 treatment, two out of seven mice did not have tumours 50 days after tumour inoculation. These results demonstrate that depletion of Treg, with anti-FR4, does not improve the therapeutic efficacy of SFVeE6,7 immunization in our murine model system.
Discussion
We focused on the questions of whether SFV-based immunization increases the number and/or activity of Treg and if depletion of Treg enhances the efficacy of a SFV-based immunization strategy in order to assess whether potential clinical application requires concomitant treatment of Treg. Interestingly, SFVeE6,7 immunization did not change numbers or activity of Treg. Furthermore, decreasing Treg numbers in vitro and in vivo, using the novel anti-FR4 antibody, did not enhance efficacy of SFVeE6,7 immunization. Both priming and proliferation of HPV-specific immune cells elicited with the SFVeE6,7 vector were not affected by immunosuppressive activity of Treg. Moreover, Treg depletion did not improve the therapeutic efficacy of SFVeE6,7 in tumour challenge experiments.
Induction of CTL responses using alphavirus vector-based immunization is very efficient [45] [46] [47] [48] [49] . In the present study, CTL responses were elicited with as few as 10 5 infectious units of SFV replicon particles, confirming our previous studies [24, [26] [27] [28] [29] . SFV immunization at dosages that induced potent CTL and antitumour responses did not enhance Treg levels in mice. Notably, even a 100-fold higher dose of SFVeE6,7 (that is, 10 7 infectious units of SFVeE6,7) did not increase the frequency of Treg in blood and spleen of immunized mice. By contrast, vaccination of mice with recombinant vaccinia virus, dendritic cells, adenylate cyclase, peptide, DNA or Listeria-based vaccines and of humans with dendritic cells resulted in Treg expansion suggesting that these therapeutic cancer vaccine candidates may stimulate tumourspecific T-cell tolerance [9] [10] [11] [12] [13] [14] 22, 23] . The fact that SFV immunization does not expand Treg suggests that this therapeutic cancer vaccine does not induce T-cell tolerance, possibly contributing to its potency.
One can envision several reasons why Treg are not induced upon SFVeE6,7 immunization. Firstly, a relatively low dose of recombinant SFV is required for a therapeutic effect as compared to other recombinant virus vaccines. Prime-boost immunization with as few as 5×10 6 SFV particles suffices for effective tumour eradication. We previously demonstrated that to induce a therapeutic effect with recombinant adenovirus, 100-1,000-fold more adenovirus compared to SFV is required [29] . A large amount of viral vector antigen might evoke a strong anti-vector response resulting in some degree of immune suppression. Secondly, upon injection, SFV replicon particles undergo only one round of infection, as RNA encoding structural proteins is not encapsidated in the replicon particles [48] . Thus, as infected cells die through apoptosis within 3 days, expression of the recombinant gene is transient and time of exposure is short. In comparison, Treg induction is more pronounced upon prolonged exposure to low doses of antigen [9, 11] . Further studies are required to elucidate which mechanisms or components of vaccines are involved in the induction of Treg.
We demonstrated that in vitro proliferation and activity of HPV-specific CTL (induced by SFVeE6,7 immunization) was barely affected by the presence or absence of Treg. Only at a very high non-physiological Treg-to-spleen cell ratio, was suppression of HPV-specific CTL proliferation observed. By contrast, Treg strongly decreased the proliferation of non-specific T-cells stimulated with anti-CD3 and anti-CD28, indicating that the sorted Treg are functional and, in line with other reports, demonstrates that these cells have the potency to inhibit the proliferation of different subsets of T-cells in vitro, including CD8 + T-cells [7, 40, 43, 50, 51] . Thus, while Treg do inhibit non-specific T-cell proliferation, we observed no marked effect of Treg on the in vitro proliferation of SFV-induced HPV-specific CTL.
TH6 antibody (anti-FR4) is a good candidate for selective Treg depletion. This anti-FR4 treatment strongly decreased Treg levels in blood and spleen for a prolonged time. Intraperitoneal injection of (6-8-weekold) mice, with as little as 25 µg of antibody, resulted in 80% reduction of the Treg population in PBMCs within 1 day. Even after 14 days, the population in PBMCs was decreased to 40% of control. Treg depletion in mice using anti-CD25 antibody or low-dose cyclophosphamide is not nearly as strong and does not persist for a long time [7, 40, 52] . For example, Lutsiak et al. [7] showed that intraperitoneal cyclophosphamide injection in mice decreased the number of Treg in spleen to 40% of control values on day 4 and, after 10 days, Treg levels were comparable to those in control mice. Moreover, anti-FR4 injection specifically decreased only Foxp3 + CD25 + cells, leaving the Foxp3 -CD25 + population unchanged. This observation is in line with recent studies and shows that anti-FR4 does not decrease the levels of cells other than Treg [53] . Importantly, anti-FR4 administration did not affect CD8 + T-cells levels. Studies from our group and from others clearly demonstrate that this population plays a crucial role in tumour immunity [29, 53] . It should, however, be noted that a high dose of anti-FR4 (100 µg) in very young mice (10-20 days of age) induces some degree of autoimmune disease [43] .
It has been demonstrated before, using anti-CD25 antibody, that reduction of the Treg numbers around the time point of immunization improves the immune responses induced by the vaccination [6] ; however, depletion with anti-CD25 at later time points does not affect immune responses. Therefore, we decided to inject anti-FR4 antibody 1 day before each SFVeE6,7 immunization. The combination of anti-FR4 treatment with SFVeE6,7 immunization, despite the strong reduction in Treg numbers, did not increase numbers and activity of HPV-specific CTL. We obtained similar results when depleting Treg with anti-CD25 (PC61 clone; MW et al., data not shown). Treg depletion (using anti-FR4) also did not improve the therapeutic efficacy of SFVeE6,7 (in comparison to the group treated with SFV only) in a mouse TC-1 tumour model. Based on our own observation and as reported on by others [54] , TC-1 tumours contain high numbers of intratumoural Treg. Therefore, the lack of improvement in therapeutic efficacy of SFVeE6,7 when combining immunization with Treg depletion cannot be explained by the absence of Treg in TC-1 tumours. Tuve et al. [54] as well as Chuang et al. [55] have also shown that Treg depletion/inhibition alone (using anti-CD25 antibody or cyclophosphamide) is not sufficient to induce efficient antitumour responses against TC-1 tumour cells. By contrast, in the latter study [55] Treg depletion did improve the efficacy of HPV DNA vaccine against TC-1 tumour cells.
In conclusion, while several other immunization strategies benefit from a combination of treatments to reduce Treg, the efficacy of SFVeE6,7 immunization was not enhanced by the depletion of Treg; furthermore, the presence of Treg did not seem to affect the SFV-induced immune response. These observations underline the strength of our SFV-based vaccination approach.
